

CITATION REPORT

List of articles citing

Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study

DOI: 10.1161/01.cir.0000054165.93055.42
Circulation, 2003, 107, 1284-90.

Source: <https://exaly.com/paper-pdf/35541366/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
194	Cardiovascular drugs and serum uric acid. 2003 , 17, 397-414		98
193	Farmacotherapie ter preventie van hartfalen. 2003 , 41, 171-172		
192	Therapies for Preventing Heart Failure. 2003 , 5, 337-343		
191	Diabetic cardiomyopathy. <i>Diabetes Care</i> , 2003 , 26, 2949-51	14.6	159
190	Drug therapy and heart failure prevention. <i>Circulation</i> , 2003 , 107, 1234-6	16.7	15
189	Trends and treatment of heart failure developing after acute myocardial infarction. 2003 , 1, 216-8		4
188	New evidence on the importance of the renin-angiotensin system in the treatment of higher-risk patients with hypertension. <i>Journal of Hypertension</i> , 2003 , 21, 1599-608	1.9	26
187	Bibliography. Current world literature. Imaging and echocardiography. 2003 , 18, 406-22		
186	ProBNP for stratifying patients with heart failure. <i>Arquivos Brasileiros De Cardiologia</i> , 2003 , 81, 239-8	1.2	2
185	Arresting cardiovascular disease progression. Early treatment may counteract high risk. 2004 , 116, 45-8		
184	Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology. <i>European Heart Journal</i> , 2004 , 25, 1454-70	9.5	176
183	[Cardiovascular prevention and rehabilitation]. 2004 , 45, 182-8		1
182	Do statins prevent heart failure in patients after myocardial infarction?. <i>Current Heart Failure Reports</i> , 2004 , 1, 156-60	2.8	1
181	Inhibition of RAAS--when is it too much?. <i>Current Heart Failure Reports</i> , 2004 , 1, 57-64	2.8	0
180	Documento de Consenso de Expertos sobre el uso de inhibidores de la enzima de conversi3n de la angiotensina en la enfermedad cardiovascular. <i>Revista Espanola De Cardiologia</i> , 2004 , 57, 1213-1232	1.5	1
179	Heart failure in women. <i>Medical Clinics of North America</i> , 2004 , 88, 1321-45, xii	7	63
178	Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction: a substudy of the Heart Outcomes Prevention Evaluation (HOPE) Trial. <i>Journal of the American College of Cardiology</i> , 2004 , 43, 2200-6	15.1	81

177	Diabetic cardiomyopathy: mechanisms, diagnosis and treatment. 2004 , 107, 539-57		250
176	New insights into degenerative mitral valve disease in dogs. 2004 , 34, 1209-26, vii-viii		41
175	Trial suggests that perindopril reduces major cardiovascular events among people with stable coronary artery disease. 2004 , 8, 66-7; discussion 68-70		
174	Acute coronary syndromes and heart failure may reflect maladaptations of trauma physiology that was shaped during pre-modern evolution. 2004 , 62, 861-7		26
173	Prevalence of unrecognized abnormal glucose tolerance in patients attending a hospital hypertension clinic. <i>American Journal of Hypertension</i> , 2004 , 17, 483-8	2.3	12
172	New insights into diastolic heart failure: role of diabetes mellitus. 2004 , 116 Suppl 5A, 64S-75S		65
171	Renal protective capacity of the angiotensin receptor antagonists. <i>Therapy: Open Access in Clinical Medicine</i> , 2004 , 1, 331-339		
170	ACE inhibitors and target organ protection. An expanded role for these antihypertensive agents?. 2004 , 116, 11-6, 19-22, 48		8
169	Retinopathy and risk of congestive heart failure. 2005 , 293, 63-9		149
168	Recent advances in hypertension, stroke, and cardiorenal disease. 2005 , 20, 258-63		7
167	Stability of ramipril in the solvents of different pH. 2005 , 37, 1179-83		15
166	Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies. 2005 , 96, 1530-6		86
165	Heart failure and its treatment in women. Role of hypertension, diabetes, and estrogen. <i>Herz</i> , 2005 , 30, 356-67	2.6	32
164	EXPERT CONSENSUS DOCUMENT ON ANGIOTENSIN CONVERTING ENZYME INHIBITORS IN CARDIOVASCULAR DISEASE. 2005 , 1, 49-69		0
163	Does load-induced ventricular hypertrophy progress to systolic heart failure?. 2005 , 289, H8-H16		144
162	Illustrating the Impact of a Time-Varying Covariate With an Extended Kaplan-Meier Estimator. 2005 , 59, 301-307		140
161	A noninferiority comparison of valsartan/hydrochlorothiazide combination versus amlodipine in black hypertensives. 2005 , 46, 508-13		31
160	Role of echocardiography in the contemporary management of chronic heart failure. 2005 , 3, 51-70		4

159	Management and outcome of patients with established coronary artery disease: the Euro Heart Survey on coronary revascularization. <i>European Heart Journal</i> , 2005 , 26, 1169-79	9.5	138
158	Strategies to reduce length of stay and costs associated with decompensated heart failure. <i>Current Heart Failure Reports</i> , 2005 , 2, 140-7	2.8	3
157	Tolerability of ramipril 10 mg daily in high-risk cardiovascular patients in Taiwan: experience from Kaohsiung Medical University Chung-Ho Memorial Hospital. 2005 , 21, 511-6		2
156	Role and optimal dosing of angiotensin-converting enzyme inhibitor therapy. <i>Heart Failure Clinics</i> , 2005 , 1, 25-37	3.3	
155	Role of neurohormonal modulators in heart failure with relatively preserved systolic function. <i>Heart Failure Clinics</i> , 2005 , 1, 77-93	3.3	3
154	Out-patient management of chronic heart failure. 2005 , 6, 1857-81		1
153	The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences. 2005 , 240, 143-56		47
152	High prevalence of microalbuminuria in chronic heart failure patients. <i>Journal of Cardiac Failure</i> , 2005 , 11, 602-6	3.3	44
151	Prevention of cardiovascular events in elderly people. 2005 , 22, 859-76		56
150	Post-transplant diabetes mellitus: risk reduction strategies in the elderly. 2006 , 23, 781-93		8
149	Ramipril: a review of its use in preventing cardiovascular outcomes in high-risk patients. 2006 , 6, 417-32		11
148	ACE inhibitors in pediatric patients with heart failure. 2006 , 8, 55-69		53
147	[Diabetic miocardiopathy]. 2006 , 127, 584-94		7
146	Diabetic cardiomyopathy. <i>Heart Failure Clinics</i> , 2006 , 2, 71-80	3.3	2
145	Prevention of ventricular remodeling, cardiac dysfunction, and heart failure. <i>Journal of Cardiac Failure</i> , 2006 , 12, e12-5	3.3	1
144	Evaluation and management of patients with heart failure and preserved left ventricular ejection fraction. <i>Journal of Cardiac Failure</i> , 2006 , 12, e80-5	3.3	13
143	Executive summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline. <i>Journal of Cardiac Failure</i> , 2006 , 12, 10-38	3.3	393
142	Cardiac cell death in early diabetes and its modulation by dietary fatty acids. 2006 , 1761, 1148-62		35

141	Should angiotensin-converting enzyme-inhibitors be used to improve outcome in patients with coronary artery disease and preserved left ventricular function?. <i>European Heart Journal</i> , 2006 , 27, 2154-7	9.5	11
140	Perioperative management of chronic heart failure. 2006 , 103, 557-75		137
139	The influences of postdischarge management by nurse practitioners on hospital readmission for heart failure. 2006 , 18, 154-60		32
138	Diagnosis and management of stage a heart failure. 2006 , 12, 146-52		1
137	Predictors of improved left ventricular systolic function in an urban cardiomyopathy program. 2006 , 98, 1622-6		3
136	Electrocardiographic strain pattern and prediction of new-onset congestive heart failure in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study. <i>Circulation</i> , 2006 , 113, 67-73	16.7	88
135	Can tissue Doppler echocardiography detect subclinical myocardial dysfunction in patients with diabetes?. 2007 , 4, 590-1		1
134	Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients. <i>Annals of Internal Medicine</i> , 2007 , 147, 311-9	8	89
133	Low-grade albuminuria and the incidence of heart failure in a community-based cohort of elderly men. <i>European Heart Journal</i> , 2007 , 28, 1739-45	9.5	58
132	Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers. 2007 , 23, 21-45		110
131	Multidisciplinary team for enhancing care for patients with acute myocardial infarction or heart failure. 2007 , 64, 1274-8		23
130	Risk Factor Management and Lifestyle Modification in Heart Failure. 2007 , 315-330		
129	The impact of angiotensin-converting enzyme inhibitor therapy on the extracellular collagen matrix during left ventricular assist device support in patients with end-stage heart failure. <i>Journal of the American College of Cardiology</i> , 2007 , 49, 1166-74	15.1	77
128	Chronic Heart Failure. 2007 ,		
127	Early imaging in heart failure: exploring novel molecular targets. 2007 , 14, 100-10		23
126	Rationale and design of the SMART Heart study: A prediction model for left ventricular hypertrophy in hypertension. 2007 , 15, 295-8		12
125	AT2 receptors: functional relevance in cardiovascular disease. 2008 , 120, 292-316		195
124	Unlocking the mysteries of diastolic function: deciphering the Rosetta Stone 10 years later. <i>Journal of the American College of Cardiology</i> , 2008 , 51, 679-89	15.1	275

123	Irbesartan in patients with heart failure and preserved ejection fraction. 2008 , 359, 2456-67		1307
122	Role and optimal dosing of angiotensin-converting enzyme inhibitors in heart failure. <i>Cardiology Clinics</i> , 2008 , 26, 1-14, v	2.5	19
121	Heart failure and diabetes mellitus: epidemiology and management of an alarming association. <i>Journal of Cardiac Failure</i> , 2008 , 14, 615-25	3.3	76
120	Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. 2008 , 372, 1174-83		755
119	Role of neurohormonal modulators in heart failure with relatively preserved systolic function. <i>Cardiology Clinics</i> , 2008 , 26, 23-40, vi	2.5	8
118	Diabetes Mellitus. 2008 , 333-342		
117	The therapeutic role of RAS blockade in chronic heart failure. 2008 , 2, 167-77		30
116	Kidney disease in patients with HIV infection and AIDS. 2008 , 47, 1449-57		80
115	Role of Neurohormones. 2008 , 345-366		
114	Echo-Based Approach to the Management of Diastolic Heart Failure. 2008 , 429-434		
113	Predictors of heart failure in patients with stable coronary artery disease: a PEACE study. <i>Circulation: Heart Failure</i> , 2009 , 2, 209-16	7.6	43
112	Prevention of heart failure with chlorthalidone in ALLHAT: placing the results into perspective. 2009 , 11, 462-5		2
111	Elevated plasma levels of TNF-alpha and interleukin-6 in patients with diastolic dysfunction and glucose metabolism disorders. <i>Cardiovascular Diabetology</i> , 2009 , 8, 58	8.7	88
110	Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. 2009 , 100, 684-92		176
109	The prognostic significance of bundle branch block in high-risk chronic stable vascular disease patients: a report from the HOPE trial. 2009 , 20, 781-7		31
108	Heart failure with preserved ejection fraction in older adults. 2009 , 122, 713-23		19
107	Perioperative optimization of the heart failure patient. 2009 , 47, 121-35		1
106	Albuminuria in heart failure: what do we really know?. 2009 , 24, 148-54		16

105	Incidence of heart failure in relation to QRS duration during antihypertensive therapy: the LIFE study. <i>Journal of Hypertension</i> , 2009 , 27, 2271-7	1.9	15
104	How should we manage heart failure developing in patients already treated with angiotensin-converting enzyme inhibitors and beta-blockers for hypertension, diabetes or coronary disease?. <i>Journal of Hypertension</i> , 2010 , 28, 1595-8	1.9	10
103	Echocardiographic evaluation of diastolic heart failure. 2010 , 13, 14-26		3
102	Diastolic dysfunction in pediatric cardiac patients: evaluation and management. 2010 , 12, 503-17		6
101	Adjuvant trastuzumab in routine clinical practice and the impact of cardiac monitoring guidelines on treatment delivery. 2010 , 19, 339-44		14
100	Preventing Heart Failure. 2010 , 1-26		
99	Vitamin B1 analog benfotiamine prevents diabetes-induced diastolic dysfunction and heart failure through Akt/Pim-1-mediated survival pathway. <i>Circulation: Heart Failure</i> , 2010 , 3, 294-305	7.6	79
98	Should targeting albuminuria be part of a cardiovascular risk reduction paradigm?. <i>Cardiology Clinics</i> , 2010 , 28, 437-45	2.5	
97	Glucose, obesity, metabolic syndrome, and diabetes relevance to incidence of heart failure. <i>Journal of the American College of Cardiology</i> , 2010 , 55, 283-93	15.1	144
96	Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?. 2010 , 70, 1215-30		33
95	Differences in determinants of left ventricular mass assessed by cardiac magnetic resonance imaging across subjects with and without previous symptomatic atherosclerotic disease. <i>International Journal of Cardiology</i> , 2010 , 138, 145-50	3.2	2
94	Gender-specific risk stratification with plasma B-type natriuretic peptide for future onset of congestive heart failure and mortality in the Japanese general population. <i>International Journal of Cardiology</i> , 2010 , 143, 124-9	3.2	11
93	Executive Summary: HFSA 2010 Comprehensive Heart Failure Practice Guideline. <i>Journal of Cardiac Failure</i> , 2010 , 16, 475-539	3.3	231
92	Section 3: Prevention of Ventricular Remodeling, Cardiac Dysfunction, and Heart Failure. <i>Journal of Cardiac Failure</i> , 2010 , 16, e38-e43	3.3	
91	Section 11: Evaluation and Management of Patients with Heart Failure and Preserved Left Ventricular Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2010 , 16, e126-e133	3.3	3
90	Simultaneous quantitative determination of metoprolol, atorvastatin and ramipril in capsules by a validated stability-indicating RP-UPLC method. <i>Scientia Pharmaceutica</i> , 2010 , 78, 821-34	4.3	13
89	Bridge to recovery: what remains to be discovered?. <i>Cardiology Clinics</i> , 2011 , 29, 531-47	2.5	7
88	Type 2 Diabetes, Pre-Diabetes, and the Metabolic Syndrome. 2011 ,		6

87	Diabetic Cardiomyopathy. 2011 ,		
86	Heart Failure as a Consequence of Diabetic Cardiomyopathy. 2011 , 408-418		2
85	Can brain natriuretic peptide be used to guide the management of patients with heart failure and a preserved ejection fraction? The wrong way to identify new treatments for a nonexistent disease. <i>Circulation: Heart Failure</i> , 2011 , 4, 538-40	7.6	30
84	Diabetes mellitus und Herzinsuffizienz. <i>Diabetologe</i> , 2011 , 7, 247-253		0.2
83	Regression of ECG-LVH is associated with lower risk of new-onset heart failure and mortality in patients with isolated systolic hypertension; The LIFE study. <i>American Journal of Hypertension</i> , 2012 , 25, 1101-9	2.3	23
82	Analysis of midwall shortening reveals high prevalence of left ventricular myocardial dysfunction in patients with diabetes mellitus: the DYDA study. <i>European Journal of Preventive Cardiology</i> , 2012 , 19, 935-43	3.9	22
81	Antihypertensives for combating dementia? A perspective on candidate molecular mechanisms and population-based prevention. <i>Translational Psychiatry</i> , 2012 , 2, e107	8.6	17
80	Short-term ACE inhibition confers long-term protection against target organ damage. <i>Hypertension Research</i> , 2012 , 35, 604-10	4.7	23
79	Diabetic cardiomyopathy: ongoing controversies in 2012. <i>Herz</i> , 2012 , 37, 880-6	2.6	16
78	Influence of sex on treatment and outcome in chronic heart failure. <i>Cardiovascular Therapeutics</i> , 2012 , 30, 182-92	3.3	11
77	Endothelial glycocalyx dysfunction in disease: albuminuria and increased microvascular permeability. <i>Journal of Pathology</i> , 2012 , 226, 562-74	9.4	211
76	Effect of a pharmacist-managed hypertension program on health system costs: an evaluation of the Study of Cardiovascular Risk Intervention by Pharmacists-Hypertension (SCRIP-HTN). <i>Pharmacotherapy</i> , 2012 , 32, 527-37	5.8	31
75	Diabetic cardiomyopathy: understanding the molecular and cellular basis to progress in diagnosis and treatment. <i>Heart Failure Reviews</i> , 2012 , 17, 325-44	5	240
74	Beta blocker use in subjects with type 2 diabetes mellitus and systolic heart failure does not worsen glycaemic control. <i>Cardiovascular Diabetology</i> , 2012 , 11, 14	8.7	25
73	Development and validation of an rp-hplc method for simultaneous determination of Ramipril and Amlodipine in tablets. <i>Journal of Pharmaceutical Analysis</i> , 2013 , 3, 440-446	14	8
72	Treatment strategies for the prevention of heart failure. <i>Current Heart Failure Reports</i> , 2013 , 10, 331-40	2.8	7
71	Protection against L-NAME-induced reduction in cardiac output persists even after cessation of angiotensin-converting enzyme inhibitor treatment. <i>Acta Physiologica</i> , 2013 , 207, 156-65	5.6	15
70	Predicting myocardial infarction and other serious cardiac outcomes using high-sensitivity cardiac troponin T in a high-risk stable population. <i>Clinical Biochemistry</i> , 2013 , 46, 5-9	3.5	39

69	A clinical risk score for heart failure in patients with type 2 diabetes and macrovascular disease: an analysis of the PROactive study. <i>International Journal of Cardiology</i> , 2013 , 162, 112-6	3.2	17
68	Direct angiotensin AT2 receptor stimulation using a novel AT2 receptor agonist, compound 21, evokes neuroprotection in conscious hypertensive rats. <i>PLoS ONE</i> , 2014 , 9, e95762	3.7	55
67	Current Status of Heart Transplantation. 2014 , 403-423		
66	Heart failure in the diabetic population - pathophysiology, diagnosis and management. <i>Archives of Medical Science</i> , 2014 , 10, 546-56	2.9	63
65	Transition of Care in Patients With Heart Failure. <i>Home Health Care Management and Practice</i> , 2014 , 26, 39-44	0.9	
64	Contrast-associated AKI and use of cardiovascular medications after acute coronary syndrome. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014 , 9, 1840-8	6.9	14
63	Cost-effectiveness of Barostim therapy for the treatment of resistant hypertension in European settings. <i>Journal of Hypertension</i> , 2014 , 32, 681-92	1.9	18
62	Pre-clinical diastolic dysfunction. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 407-16	15.1	206
61	Management of ACCF/AHA Stage A and B patients. <i>Cardiology Clinics</i> , 2014 , 32, 63-71, viii	2.5	4
60	Relationship of left ventricular systolic function to persistence or development of electrocardiographic left ventricular hypertrophy in hypertensive patients: implications for the development of new heart failure. <i>Journal of Hypertension</i> , 2014 , 32, 2472-8; discussion 2478	1.9	5
59	Effects of Statins on Left Ventricular Diastolic Function in Patients with Dyslipidemia and Diastolic Dysfunction (Stat-LVDF Study). <i>Biological and Pharmaceutical Bulletin</i> , 2015 , 38, 1404-9	2.3	5
58	Stage A Heart Failure Is Not Adequately Recognized in US Adults: Analysis of the National Health and Nutrition Examination Surveys, 2007-2010. <i>PLoS ONE</i> , 2015 , 10, e0132228	3.7	13
57	Bariatric Surgery can Lead to Net Cost Savings to Health Care Systems: Results from a Comprehensive European Decision Analytic Model. <i>Obesity Surgery</i> , 2015 , 25, 1559-68	3.7	66
56	Heart Failure Prevention and Team-based Interventions. <i>Heart Failure Clinics</i> , 2015 , 11, 349-58	3.3	8
55	Targeting Preclinical Diastolic Dysfunction to Prevent Heart Failure: Contemporary Insights. <i>Current Cardiovascular Risk Reports</i> , 2015 , 9, 1	0.9	
54	Prevention of Heart Failure in Patients with Chronic Kidney Disease. <i>Current Cardiovascular Risk Reports</i> , 2015 , 9, 1	0.9	1
53	Heart Failure in Patients with Preserved Ejection Fraction: Questions Concerning Clinical Progression. <i>Journal of Cardiovascular Development and Disease</i> , 2016 , 3,	4.2	4
52	Present Insights on Cardiomyopathy in Diabetic Patients. <i>Current Diabetes Reviews</i> , 2016 , 12, 384-395	2.7	22

51	InnovaSEC in Action: Cost-effectiveness of Barostim in the Treatment of Refractory Hypertension in Spain. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016 , 69, 563-71	0.7	1
50	Survival probabilities with time-dependent treatment indicator: quantities and non-parametric estimators. <i>Statistics in Medicine</i> , 2016 , 35, 1032-48	2.3	9
49	Elastic, silk-cardiac extracellular matrix hydrogels exhibit time-dependent stiffening that modulates cardiac fibroblast response. <i>Journal of Biomedical Materials Research - Part A</i> , 2016 , 104, 3058-3072	5.1	36
48	Pharmacist-involved care for patients with heart failure and acute coronary syndrome: a systematic review with qualitative and quantitative meta-analysis. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2016 , 41, 145-57	2.2	22
47	Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2016 , 134, e535-e578	16.7	164
46	InnovaSEC en acci3n: coste-efectividad de Barostim para el tratamiento de la hipertensi3n arterial refractaria en Espa3a. <i>Revista Espanola De Cardiologia</i> , 2016 , 69, 563-571	1.5	1
45	Left ventricular hypertrophy by ECG versus cardiac MRI as a predictor for heart failure. <i>Heart</i> , 2017 , 103, 49-54	5.1	22
44	Current Perspectives on Systemic Hypertension in Heart Failure with Preserved Ejection Fraction. <i>Current Hypertension Reports</i> , 2017 , 19, 12	4.7	14
43	MicroRNAs in Diabetes and Its Vascular Complications. <i>Cardiac and Vascular Biology</i> , 2017 , 39-59	0.2	
42	Non-coding RNAs in the Vasculature. <i>Cardiac and Vascular Biology</i> , 2017 ,	0.2	
41	Using recurrent neural network models for early detection of heart failure onset. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2017 , 24, 361-370	8.6	377
40	Heart Failure and Hypertension: Importance of Prevention. <i>Medical Clinics of North America</i> , 2017 , 101, 19-28	7	20
39	Cost-Utility Analysis of Bariatric Surgery in Italy: Results of Decision-Analytic Modelling. <i>Obesity Facts</i> , 2017 , 10, 261-272	5.1	15
38	Heart Failure: The Most Important, Preventable, and Treatable Cardiovascular Complication of Type 2 Diabetes. <i>Diabetes Care</i> , 2018 , 41, 11-13	14.6	49
37	Cost-effectiveness analysis of bariatric surgery for morbid obesity in Belgium. <i>Journal of Medical Economics</i> , 2018 , 21, 365-373	2.4	8
36	Lessons Learned From Multi-regional Trials With Signals of Treatment Effect Heterogeneity. <i>Therapeutic Innovation and Regulatory Science</i> , 2018 , 216847901880542	1.2	
35	Impact of renin-angiotensin system inhibitors on clinical outcomes and ventricular remodelling after transcatheter aortic valve implantation: rationale and design of the RASTAVI randomised multicentre study. <i>BMJ Open</i> , 2018 , 8, e020255	3	14
34	Heart Failure. <i>Annals of Internal Medicine</i> , 2018 , 168, ITC81-ITC96	8	5

33	Interpretation of Clinical Trials in the Context of Personalized/Individualized Medicine and End of Life Issues. <i>Cardiovascular Medicine</i> , 2019 , 155-162	0.1	
32	LSTM Model for Prediction of Heart Failure in Big Data. <i>Journal of Medical Systems</i> , 2019 , 43, 111	5.1	55
31	Heart Failure. <i>Cardiovascular Medicine</i> , 2019 ,	0.1	
30	ACE-Triggered Hypertension Incites Stroke: Genetic, Molecular, and Therapeutic Aspects. <i>NeuroMolecular Medicine</i> , 2020 , 22, 194-209	4.6	4
29	Heart Failure Prevention for All: Treatment Is Good, Prevention Is Better. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 1466-1467	15.1	1
28	Efficacy and Safety of Bushenjiangya-Optimized Granule for Left Ventricular Diastolic Dysfunction in Hypertensive Patients: A Double-Blind, Randomized, Placebo-Controlled Trial. <i>Evidence-based Complementary and Alternative Medicine</i> , 2020 , 2020, 7190352	2.3	
27	Hypertensive coronary microvascular dysfunction: a subclinical marker of end organ damage and heart failure. <i>European Heart Journal</i> , 2020 , 41, 2366-2375	9.5	20
26	Understanding the early mortality benefit observed in the PARADIGM-HF trial: considerations for the management of heart failure with sacubitril/valsartan. <i>Vascular Health and Risk Management</i> , 2020 , 16, 41-51	4.4	10
25	Highly Sensitive and Selective Electrochemical Sensor Based on Polyglycine Modified Glassy Carbon Electrode for Simultaneous Determination of Amlodipine and Ramipril from Biological Samples. <i>Journal of the Electrochemical Society</i> , 2020 , 167, 027511	3.9	4
24	Patient experiences of pharmacist independent prescriber-led post-myocardial infarction left ventricular systolic dysfunction clinics. <i>International Journal of Pharmacy Practice</i> , 2021 , 29, 55-60	1.7	0
23	Prospective ARNI vs. ACE inhibitor trial to Determine Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics. <i>European Journal of Heart Failure</i> , 2021 , 23, 1040-1048	12.3	29
22	The progressive pathway of microalbuminuria: from early marker of renal damage to strong cardiovascular risk predictor. <i>Journal of Hypertension</i> , 2010 , 28, 2357-69	1.9	65
21	HiTANet: Hierarchical Time-Aware Attention Networks for Risk Prediction on Electronic Health Records. 2020 ,		12
20	Comparison of positive cases for B-type natriuretic peptide and ECG testing for identification of precursor forms of heart failure in an elderly population. <i>International Heart Journal</i> , 2005 , 46, 477-87	1.8	7
19	Diminished renal function and the incidence of heart failure. <i>Current Cardiology Reviews</i> , 2009 , 5, 223-7	2.4	7
18	Epidemiology, Pathophysiology, and Management of Native Atrioventricular Valve Regurgitation in Heart Failure Patients. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 713658	5.4	
17	Pr?vention der KHK. <i>CME (Berlin, Germany)</i> ,	0	
16	Angiotensin II and Inflammation. 2007 , 91-110		

15	Cardiovascular Pharmacology. 2008 , 118-163		
14	Atheromatous Embolization. 2010 , 2422-2434		
13	Risk Reduction in the Diabetic Patient. 2011 , 281-315		1
12	Cardiovascular Pharmacology. 2011 , 235-295		1
11	7th Brazilian Guideline of Arterial Hypertension: Chapter 8 - Hypertension and Associated Clinical Conditions. <i>Arquivos Brasileiros De Cardiologia</i> , 2016 , 107, 44-48	1.2	2
10	Renal protective capacity of the angiotensin receptor antagonists. <i>Therapy: Open Access in Clinical Medicine</i> , 2004 , 1, 331-339		
9	More than just hype. <i>Cmaj</i> , 2003 , 168, 1646-7; author reply 1647-8		3.5
8	A Study on Microalbuminuria in Non-Diabetic Hypertensive Patients Attending a Tertiary Care Hospital in South India. <i>Journal of Evolution of Medical and Dental Sciences</i> , 2021 , 10, 3665-3669	0.1	
7	Kidney and heart failure outcomes associated with SGLT2 inhibitor use.. <i>Nature Reviews Nephrology</i> , 2022 ,	14.9	4
6	Mechanisms for the development of heart failure and improvement of cardiac function by angiotensin-converting enzyme inhibitors. <i>Scripta Medica</i> , 2022 , 53, 51-76	0.3	1
5	Endothelial glycocalyx is damaged in diabetic cardiomyopathy: angiotensin 1 restores glycocalyx and improves diastolic function in mice.. <i>Diabetologia</i> , 2022 , 65, 879	10.3	2
4	Cardiopulmonary resuscitation. 947-954		
3	Cardiac failure in the intensive care unit. 966-971		
2	Prediction of heart failure 1 year before diagnosis in general practitioner patients using machine learning algorithms: a retrospective case-control study. 2022 , 12, e060458		0
1	Risk scores for predicting incident heart failure admission in patients with chronic coronary syndromes: validation in a prospective, monocentric, long-term, cohort study.		0